SCHEMBL5495032

SCHEMBL5495032

N#Cc1cc(F)c(C(N)=O)cc1F

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 2/20 0.52
CYP11B2 P19099 2/20 0.43
DGAT1 O75907 1/20 0.43
ROCK2 O75116 1/20 0.41
KHK P50053 1/20 0.37
CASP1 P29466 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.35
PARP10 Q53GL7 2/20 0.35
PARP15 Q460N3 1/20 0.35
ADRA1D P25100 1/20 0.35
GPR52 Q9Y2T5 2/20 0.34
JAK2 O60674 1/20 0.34
PARP1 P09874 1/20 0.34
CYP11B1 P15538 1/20 0.34
CDC7 O00311 1/20 0.34
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31171398 0.92 TRPV4 (0.47) TRPV4CYP11B2DGAT1ROCK2KHK
SCHEMBL8300964 0.82 TRPV4 (0.48) TRPV4
SCHEMBL811340 0.81 DGAT1 (0.58) DGAT1ROCK2CASP1PARP10PARP15
SCHEMBL8004361 0.81 TRPV4 (0.47) TRPV4CYP11B2KHKCYP11B1PDE4A
SCHEMBL8006776 0.81 TRPV4 (0.47) TRPV4CYP11B2KHKCYP11B1PDE4A
SCHEMBL8299340 0.81 TRPV4 (0.47) TRPV4CYP11B2CYP11B1
SCHEMBL7752581 0.78 TRPV4 (0.44) TRPV4CYP11B2KHKCYP11B1PDE4A
SCHEMBL2323641 0.77 DGAT1 (0.54) CYP11B2DGAT1ROCK2CASP1PARP10
SCHEMBL15920675 0.77 GAA (0.44) TRPV4
SCHEMBL410466 0.77 GAA (0.48) TRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1656360-B1 THIAZOLINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA NV (BE) 2007-08-15 EP disclosed
EP-1656360-A1 THIAZOLINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-17 EP disclosed
US-20050014952-A1 Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) JASSEN PHARMACEUTICA N.V. (BE) 2005-01-20 US disclosed
WO-2004113309-A1 THIAZOLINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014952-A1 Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) AR, NR5A1, NR5A2 TRPV4 665/4885CYP11B2 31/4885DGAT1 1758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.